Tags

Type your tag names separated by a space and hit enter

Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
Emerg Microbes Infect. 2021 Dec; 10(1):664-676.EM

Abstract

Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63, and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titres mounted until days 22-28, whereas HCoV-OC43 antibody titres increased until days 15-21 and then plateaued until day 46. However, IgG titres against HCoV-NL63, -229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titres were significantly higher in patients with severe disease than those in mild patients at days 1-21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1-10 PSO, HCoV-OC43 S-IgG titres correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients.

Authors+Show Affiliations

NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. Key Laboratory of Respiratory Disease Pathogenomics and Christophe Mérieux Laboratory, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, People's Republic of China.Jin Yin-tan Hospital, Wuhan, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.Emergency Department of Infectious Diseases of Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. Key Laboratory of Respiratory Disease Pathogenomics and Christophe Mérieux Laboratory, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, People's Republic of China.Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, People's Republic of China.Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, People's Republic of China. Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China.Tsinghua University School of Medicine, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, People's Republic of China. Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, People's Republic of China. Department of Respiratory Medicine, Capital Medical University, Beijing, People's Republic of China.NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China. Key Laboratory of Respiratory Disease Pathogenomics and Christophe Mérieux Laboratory, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33734013

Citation

Guo, Li, et al. "Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates With Disease Severity in COVID-19 Patients: a Retrospective Study." Emerging Microbes & Infections, vol. 10, no. 1, 2021, pp. 664-676.
Guo L, Wang Y, Kang L, et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10(1):664-676.
Guo, L., Wang, Y., Kang, L., Hu, Y., Wang, L., Zhong, J., Chen, H., Ren, L., Gu, X., Wang, G., Wang, C., Dong, X., Wu, C., Han, L., Wang, Y., Fan, G., Zou, X., Li, H., Xu, J., ... Wang, J. (2021). Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerging Microbes & Infections, 10(1), 664-676. https://doi.org/10.1080/22221751.2021.1905488
Guo L, et al. Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates With Disease Severity in COVID-19 Patients: a Retrospective Study. Emerg Microbes Infect. 2021;10(1):664-676. PubMed PMID: 33734013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. AU - Guo,Li, AU - Wang,Yeming, AU - Kang,Liang, AU - Hu,Yongfeng, AU - Wang,Linghang, AU - Zhong,Jingchuan, AU - Chen,Hong, AU - Ren,Lili, AU - Gu,Xiaoying, AU - Wang,Geng, AU - Wang,Conghui, AU - Dong,Xiaojing, AU - Wu,Chao, AU - Han,Lianlian, AU - Wang,Ying, AU - Fan,Guohui, AU - Zou,Xiaohui, AU - Li,Haibo, AU - Xu,Jiuyang, AU - Jin,Qi, AU - Cao,Bin, AU - Wang,Jianwei, PY - 2021/3/19/pubmed PY - 2021/4/13/medline PY - 2021/3/18/entrez KW - Cross-reactivity KW - HCoV-OC43 KW - SARS-CoV-2 KW - antibody KW - disease severity SP - 664 EP - 676 JF - Emerging microbes & infections JO - Emerg Microbes Infect VL - 10 IS - 1 N2 - Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63, and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titres mounted until days 22-28, whereas HCoV-OC43 antibody titres increased until days 15-21 and then plateaued until day 46. However, IgG titres against HCoV-NL63, -229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titres were significantly higher in patients with severe disease than those in mild patients at days 1-21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1-10 PSO, HCoV-OC43 S-IgG titres correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients. SN - 2222-1751 UR - https://www.unboundmedicine.com/medline/citation/33734013/Cross_reactive_antibody_against_human_coronavirus_OC43_spike_protein_correlates_with_disease_severity_in_COVID_19_patients:_a_retrospective_study_ L2 - https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1905488 DB - PRIME DP - Unbound Medicine ER -